UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37813 SYROS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 45-3772460 (State or Other Jurisdiction of Incorporation or Organ ...

An Expression Makes a World of Difference March 2022 Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, research and clinical development plans, collaborations, future operations, future financial position, future revenue ...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2021 Financial Results Conference Call March 15, 2022 8:30 AM ET Company Participants Courtney Solberg - Manager, Corporate Communications and Investor Relations Nancy Simonian - Chief Executive Officer Jason Haas - Chief Financial Officer David Roth - Chief Medical Officer Kristin Stephens - Chief Development Office Eric Olson - Chief Scientific Officer Conley Chee - Chief Commercial Officer Conference Call Participants Ted Tenthoff - Piper Sandler Phil Nadeau - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37813 SYROS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 45-3772460 (State or other jurisdic ...

Tyme Technologies, Inc. (TYME) Q2 2021 Earnings Conference Call November 8, 2021 8:30 AM ET Company Participants Richie Cunningham – Chief Executive Officer Lisa Wilson – Investor Relations Frank Porfido – Chief Financial Officer Dr. Yan Von Tornaut – Acting Chief Medical Officer Dr. Jonathan Eckard – Chief Business Officer Conference Call Participants Operator Good day, ladies and gentlemen. And welcome to TYME Technologies Second Fiscal Quarter 2022 Earnings Results call. At this time, all participant lin ...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2021 Earnings Conference Call November 5, 2021 8:30 AM ET Company Participants Courtney Solberg - Manager, Corporate Communications Nancy Simonian - President and Chief Executive Officer Jason Haas - Chief Financial Officer David Roth - Chief Medical Officer Kristin Stephens - Chief Development Office Eric Olson - Chief Scientific Officer Conference Call Participants Ted Tenthoff - Piper Jaffray Phil Nadeau - Cowen and Company Jason Butler - JMP Securities Mark B ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37813 SYROS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 45-3772460 (State or Other Jurisdiction of Incorporation or O ...

TYMEO Scientific Solutions Without Compromise Corporate Presentation October 2021 m n G 4 D S ব N n O C C N - ш W F Safe Harbor Statement 2 In addition to historical information, this presentation contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. Such forward-looking statements within this presentation include, without limitation, statements regarding our drug candidates (including SM-88 and TYME- 18) and their clinical p ...

| --- | --- | --- | --- | |--------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | An Expression Makes a World of Difference | | | | | September 2021 | | | | Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including s ...

| --- | --- | --- | --- | |-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, research and clinical development plans, collaborations, future operat ...